miRNA-9 delivery using lactosome, a newly-developed drug delivery system, in the treatment of rheumatoid arthritis

2022 Fiscal Year Research-status Report

• Project/Area Number: 22K16341
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: LEE WENSHI 東京医科歯科大学, 大学院医歯学総合研究科, 非常勤講師 (30883590)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: miRNA-9 / rheumatoid arthritis / arthritis mouse model / drug delivery system

Outline of Annual Research Achievements

We injected lactosome-mir9 intravenously into collagen-induced arthritis mouse model, with lactosome-control siRNA as control group.
The mean arthritic score was relatively lower in miR-9 group compared to the control group. The histological assessments for the joints are currently under progress.

Current Status of Research Progress

3: Progress in research has been slightly delayed.

Reason

The main reason for this is that the major molecules for lactosome conjugation was out of stock due to the COVID-19 pandemic. The experiments go smooth once we received the molecules and lactosome.

Strategy for Future Research Activity

To repeat the experiments with larger sample size and to use serum transfer arthritis model to repeat the experiments.
Further, to inject lactosome repeatedly to compare the difference between one shot and booster effects.

Causes of Carryover

To repeat animal experiments with different approaches